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To the editor: Granulosa cell tumor (GCT) of the ovary is cha­
rac  terized by a relatively indolent natural history with a pro­
pensity for late recurrence and long­term survival. The median 
time to recurrence is 4 to 6 years after the initial diagnosis [1]. 
Disease recurrence often presents within the pelvis as a local 
mass, in the retroperitoneal lymph nodes, or as disseminated 
peritoneal metastases [1,2]. There is no standard management 
for recurrent GCT. Various treatment options include surgery 
with/without chemotherapy and/or radiotherapy. Patients 
with peritoneal metastases are often considered inoperable 
with treatment largely directed at palliation of symptoms. Five 
patients with recurrent GCT with peritoneal metastases from 
our institution were treated with cytoreductive surgery (CRS).
The mean (standard deviation) age of five women at the time 
of CRS was 49 (10) years. Prior to CRS, all five patients were fol­
lowed­up after initial staging surgery performed by the gyn­
aecologic oncology surgeon. The initial staging surgery was a 
total abdominal hysterectomy with bilateral salpingo­oopho­
rectomy in the three patients. Two patients required opted 
for fertility conservation and underwent a unilateral salpingo­
oophorectomy. Due to the localized disease in the ovary, 
none of the patients received adjuvant treatment after the 
initial surgery. The median disease­free survival after primary 
treatment was 6 years (range, 6 to 12 years). Treatment of first 
recurrence involved CRS in patient one and patient three, 
sys  temic chemotherapy in patient two, debulking surgery in 
patient four and systemic chemotherapy with radiotherapy 
in patient five. The three patients who did not undergo CRS 
eventually underwent CRS for management of persistent re­
current disease. The detailed summary of the patients’ clinical 
pathway is presented in Table 1. 
In total, eight cytoreductive surgeries using peritonectomy 
procedures were performed in five patients, of which one pa­
tient received intraoperative hyperthermic intraperitoneal cis­
platin for 90 minutes at 42
oC. There was no in­hospitalization 
treatment related mortality. The median length of operation 
was 5.3 hours (range, 3.3 to 10 hours). The median length of 
stay in hospital was 10 days (range, 7 to 87 days). Patients one 
and two recovered uneventfully. Severe postoperative compli­
cations as graded according to the National Cancer Institute’s 
Common Toxicity Criteria occurred in patient three at the time 
of peritonectomy for the fourth recurrence, in patient four at 
the time of peritonectomy for the second recurrence, and in 
patient five at the time of first peritonectomy for treatment for 
third recurrence. Patient three had a 24 day hospital stay after 
suffering from a grade III postoperative complication, requir­
ing percutaneous drainage of a retroperitoneal abscess under 
radiological guidance. Patient four remained hospitalized for 
87 days following grade IV postoperative complications with 
re  nal impairment secondary to intraperitoneal cisplatin, right 
pleu  ral effusion requiring chest drain placement, recto­cysto­
vaginal fistula and sepsis. Patient five had a 12 day hospital 
stay after suffering from grade III postoperative complication, 
re  quiring percutaneous drainage of a right upper quadrant 
collection.
Following CRS, patient one, four and five are disease free. 
However, disease recurrence was seen in patient two and 
three in whom repeat peritonectomy was performed. Patient 
two developed recurrence 38 months later, and was treated 
with repeat peritonectomy. Patient three developed multiple 
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Table 1. Summary of clinical pathway of four patients with peritoneal metastases from recurrent granulosa cell tumor of the ovary
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age at diagnosis (yr) 36 53 34 35 25
Primary surgical treatment Right salpingo-
oophorectomy
Total hysterectomy, 
bilateral salpingo-
oophorectomy, 
omentectomy
Total hysterectomy, 
bilateral salpingo-
oophorectomy
Left salpingo-
oophorectomy
Total hysterectomy, 
bilateral salpingo-
oophorectomy
Time to first recurrence 
(yr)
6 9 12 6 6
Type of first recurrence Intra-abdominal mass 
with peritoneal disease
Peritoneal disease Intra-thoracic mass and 
Intra-abdominal mass 
with peritoneal disease
Retroperitoneal nodal 
mass and few peritoneal 
nodules 
Peritoneal disease
Type of treatment for first 
recurrence
Omentectomy + 
splenectomy, pelvic 
peritonectomy, total 
anterior parietal 
peritonectomy, 
diaphragmatic 
peritonectomy, 
total hysterectomy 
left salpingo-
oophorectomy*
Bleomycin, etoposide, 
carboplatin
Right lower lobectomy, 
liver resection, right 
diaphragmatic 
peritonectomy, right 
adrenalectomy*
Debulking surgery with 
excision of peritoneal 
nodules
Bleomycin, etoposide, 
carboplatin and 
radiotherapy
Time to second recurrence 
(mo)
- 44 30 40 81
Type of second recurrence - Peritoneal disease Peritoneal disease Peritoneal disease Single lung metastasis, 
peritoneal disease
Type of treatment for 
second recurrence
- Pelvic peritonectomy* Pelvic peritonectomy Pelvic peritonectomy, 
total anterior parietal 
peritonectomy, 
hyperthermic 
intraperitoneal 
cisplatin*
Bleomycin, etoposide, 
carboplatin
Time to third recurrence 
(mo)
- 38 29 - 91
Type of third recurrence - Peritoneal disease Nodal disease - Peritoneal disease and 
stable lung metastasis
Type of treatment for third 
recurrence
- Diaphragmatic 
peritonectomy, 
cytoreduction on small 
bowel surface, stripping 
of mesentry
Debulking surgery - Total anterior parietal 
peritonectomy, pelvic 
peritonectomy, 
right diaphragmatic 
peritonectomy, 
stripping of 
omental bursa with 
cholecystectomy, 
cytoreduction on 
small bowel surface, 
small bowel resection, 
anterior resection, right 
hepatectomy, right 
adrenalectomy*
Time to fourth recurrence 
(mo)
- - 30 - -
Type of fourth recurrence - - Peritoneal disease - -
Type of treatment for 
fourth recurrence
- - Cytoreduction of small 
bowel surface, small 
bowel resection, distal 
pancreatectomy, 
splenectomy, 
diaphragmatic 
peritonectomy
- -
Survival following 
peritonectomy (mo)
38 44 95 33 10
Number of recurrence 
following 
peritonectomy
0 1 3 0 0
Current disease status NED NED NED NED NED
*Refer to time of first peritonectomy.
NED, no evidence of disease.Terence C. Chua, et al.
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recurrences 30 months after first peritonectomy, where a re­
peat peritonectomy was performed. A further disease­free in­
terval of 29 months was achieved before the development of 
a nodal recurrence which was treated with debulking surgery 
where lymphadenectomy was performed. Subsequently, the 
patient developed peritoneal recurrence 30 months later and 
underwent a third repeat peritonectomy. With a median fol­
low­up of 38 months after the first peritonectomy treatment, 
all five patients are still alive 10 to 95 months after treatment 
with no evidence of disease. 
Disseminated peritoneal metastasis of GCT is characterized 
intraoperatively by the extensive presence of macroscopic 
whitish tumor nodules of variable sizes and consistency that 
may coalesce to form plaques or masses within the abdomi­
nopelvic cavity. These nodules and plaques may also layer 
out and line the entire peritoneal surface. This phenomenon 
in recurrent GCT has been previously described [3]. It occurs 
as a result of direct serosal invasion, perforation or rupture of 
the primary ovarian tumor. It may also be related to iatrogenic 
mechanisms during invasive procedures such as fine­needle 
cytology or spillage of tumor content during surgical inter­
vention. As with other forms of malignancies that disseminate 
extensively on the peritoneal surface, such as colon cancer, 
epithelial ovarian cancer and peritoneal mesothelioma, perito­
neal metastases has traditionally been regarded incurable and 
is associated with a poor prognosis. Patients with advanced 
ovarian cancer have a 5­year survival of less than 25% [4]. In a 
Korean multicenter study of 113 patients with GCT, FIGO stage 
predicted for recurrence in patients after initial treatment [5].
Surgical treatment of peritoneal metastases from recurrent 
GCT is unduly challenging. Conventional debulking surgery 
is insufficient in attaining complete cytoreduction. Peritonec­
tomy procedures, as described by Sugarbaker [6], is a surgical 
procedure that involves the removal of the diseased perito­
neum as a means of achieving complete cytoreduction. It has 
brought about a new paradigm into the treatment of perito­
neal metastases. We demonstrate the feasibility of employing 
peritonectomy procedures to achieve complete cytoreduc­
tion in the five patients and have demonstrated prolonged 
disease­free survival ranging from 10 to 95 months. In patients 
who develop recurrence, repeat peritonectomy is a reason­
able option, as shown in patient three, where a disease­free 
interval of 29 months was achieved after the second perito­
nectomy. This may be a reflection of the indolent biology of 
this disease where a long­term survival can be achieved if 
complete cytoreduction is performed. Nonetheless, severe 
postoperative complications may occur as a result of the pro­
cess of aggressive cytoreduction. This must be balanced with 
any hope of long­term survival this treatment may offer. 
Various other treatment modalities are employed in the 
treatment of recurrent disease; chemotherapy, radiotherapy 
and hormonal therapy. The common chemotherapy regime 
used in this setting is a combination of bleomycin, etoposide, 
and cisplatin. Although, the response rate to this regimen 
ranges between 51 to 90%, the effectiveness of this treatment 
remains poor with a median disease­free survival of only 14 
to 24 months [7,8]. Outcomes of radiotherapy and hormonal 
therapy are also poor, with response rates being 43 and 40% 
respectively. Overall median survival following radiotherapy 
treatment is 156 months in responders and 12 months in 
non­responders [9]. Patients treated with hormonal therapy 
develop progressive disease after 8 months [10]. Therefore, 
the only available effective treatment that has demonstrated 
a prolonged survival is surgery [1,3]. 
From our experience, non­surgical management of recurrent 
GCT is only employed in the setting of un­resectable disease. 
In selected patients who are suitable to undergo surgery, max­
imal cytoreduction with a curative intent that includes tumor 
resection, retroperitoneal lymphadenectomy and peritonec­
tomy should be considered. Our report is the first to describe 
the use of peritonectomy procedures to achieve maximal 
cytoreduction in patients with recurrent GCT, demon  strating 
the feasibility and safety of this treatment option. We have not 
begun routinely administering intraoperative hyperthermic 
intraperitoneal chemotherapy for patients with peritoneal 
metastases from GCT; however it may be worth considering 
given the 51 to 90% response rate observed when adminis­
tered intravenously for which may potentially be higher when 
administered intraperitoneally. Following evidence from the 
literature that suggests that maximal cytoreduction is an im­
portant aspect of treatment in recurrent GCT [1], we have de­
scribed the use of peritonectomy to achieve complete cytore­
duction in patients with peritoneal metastases from recurrent 
GCT. 
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